Drug Profile
Fibrinogen receptor antagonist - RELIEF THERAPEUTICS Holding
Alternative Names: Pro-Ser-Hyp-Gly-Asp-Trp - RELIEF THERAPEUTICS HoldingLatest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Peptides
- Mechanism of Action Fibrinogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Vascular disorders in Switzerland (unspecified route)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Vascular-disorders in Switzerland
- 21 Sep 2016 Fibrinogen receptor antagonist - RELIEF THERAPEUTICS Holding is available for licensing as of 21 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/